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OBJECTIVE — To determine insulin resistance and response in patients with polycystic
ovary syndrome (PCOS) and normal glucose tolerance (NGT), impaired fasting glucose (IFG),
impaired glucose tolerance, and combined glucose intolerance (CGI).
RESEARCH DESIGN AND METHODS — In this cross-sectional study, 143 patients
with PCOS (diagnosed on the basis of National Institutes of Health criteria) underwent oral
glucose tolerance testing (OGTT), and 68 patients also had frequently sampled intravenous
glucose tolerance tests. Changes in plasma glucose, insulin, cardiovascular risk factors, and
androgens were measured.
RESULTS — Compared with patients with NGT, those with both IFG and CGI were signiﬁ-
cantly insulin resistant (homeostasis model assessment 3.3  0.2 vs. 6.1  0.9 and 6.4  0.5,
P  0.0001) and hyperinsulinemic (insulin area under the curve for 120 min 973  69 vs.
1,470  197 and 1,461  172 pmol/l, P  0.0001). Insulin response was delayed in patients
with CGI but not in those with IFG (2-h OGTT, insulin 1,001  40 vs. 583  45 pmol/l, P 
0.0001).ComparedwiththeNGTgroup,theCGIgrouphadalowerdispositionindex(1,615
236 vs. 987  296, P  0.0234) and adiponectin level (11.1  1.1 vs. 6.2  0.8 ng/ml, P 
0.0096). Compared with the insulin-resistant tertile of the NGT group, those with IFG had a
reduced insulinogenic index (421  130 vs. 268  68, P  0.05). Compared with the insulin-
sensitivetertileoftheNGTgroup,theresistanttertilehadhighertriglycerideandhigh-sensitivity
C-reactive protein (hs-CRP) and lower HDL cholesterol and sex hormone–binding globulin
(SHBG).Intheentirepopulation,insulinresistancecorrelateddirectlywithtriglyceride,hs-CRP,
and the free androgen index and inversely with SHBG.
CONCLUSIONS — Patients with PCOS develop IFG and CGI despite having signiﬁcant
hyperinsulinemia.PatientswithIFGandCGIexhibitsimilarinsulinresistancebutverydifferent
insulin response patterns. Increases in cardiac risk factors and free androgen level precede overt
glucose intolerance.
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W
omen with polycystic ovary syn-
drome (PCOS) are at risk for im-
paired glucose tolerance (IGT),
type 2 diabetes, and gestational diabetes
mellitus (1) owing to abnormalities in in-
sulinsecretionandaction(2–4).Thespe-
ciﬁc defect is increased serine and
decreased tyrosine phosphorylation of
the insulin receptor (5). Patients who de-
velop glucose intolerance have a relative
decrease in insulin secretion as well (4).
Women with PCOS are hyperinsulinemic
compared with weight-matched control
subjects (1). Hyperinsulinemia worsens
and insulin sensitizers improve ovarian
dysfunction and hyperandrogenemia in
PCOS (6). Therefore, assessing glucose
homeostasis by an oral glucose tolerance test
(OGTT) has become a common practice.
Deﬁnition and interpretation of glu-
cose intolerance have changed in recent
years. The fasting glucose cutoff for dia-
betes was reduced from 140 to 126 mg/dl
and the new term, impaired fasting glu-
cose (IFG), was introduced for the values
between 110 and 125 mg/dl (7). In 2003,
thecutoffvaluefornormalfastingglucose
was reduced to 100 mg/dl (8). In addi-
tion, recent research demonstrated that
the pathophysiology of isolated IFG dif-
fers from that of isolated IGT (deﬁned by
glucose levels 140 mg/dl at2ho fa n
OGTT). The former results from hepatic
insulin resistance, whereas the latter re-
sults from peripheral insulin resistance
(9,10). Those individuals who exhibit
combined glucose intolerance (CGI)
have resistance at both sites. In addition,
cardiovascular risk factors are more
commonly encountered with glucose in-
tolerance (IGT and CGI) than with iso-
lated IFG (11).
Although glucose intolerance is
foundinone-thirdofpatientswithPCOS,
so far only one study investigated the in-
sulin resistance and secretion in patients
with PCOS with IFG or IGT/CGI (12).
Our study was undertaken to determine
thedifferencesininsulinsecretionandac-
tion in patients with PCOS exhibiting dif-
ferent types of glucose intolerance.
RESEARCH DESIGN AND
METHODS— A total of 143 women
(108 [76%] white, 17 [12%] African
American,8[6%]Hispanic,5[3%]Amer-
icanIndian,and5[3%]Asian)withPCOS
(diagnosed by National Institutes of
Health criteria), aged 18–45 years
(means  SEM 26.1  0.9 years) with
BMI 20–50 kg/m
2 were recruited at the
University of California (UC), Davis (Sac-
ramento, CA) (n  68) and Yale Univer-
sity School of Medicine (New Haven, CT)
(n  75). The study was approved by the
institutional review boards of both insti-
tutions. The subjects at UC Davis pro-
vided written informed consent, and they
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A.J.D. Patients using insulin sensitizers or
medicines affecting lipids, weight, or in-
sulin sensitivity within 2 months; having
diabetes, untreated hypothyroidism, or
systemic illnesses (i.e., renal, hepatic, and
gastrointestinal); smoking; and drinking
2 servings of alcohol per week were ex-
cluded. Pregnant, postpartum, or lactat-
ing women were excluded. The studies
werecarriedoutattheClinicalandTrans-
lationalScienceCenteratUCDavisandat
Yale University School of Medicine Re-
productive Endocrinology and Fertility
Center. The subjects consumed their ha-
bitual diets and were weight-stable.
Fasting blood tests and OGTT were
done in all subjects. Subjects recruited at
UC Davis also underwent a frequently
sampled intravenous glucose tolerance
test (FSIVGTT).
Anthropometric measurements
Weight was measured using a Tanita
BWB800-P digital medical scale, and
height was measured using an Ayrton
model S100 stadiometer.
OGTT
A standard OGTT was performed using
75 g of glucose (Glucola). Blood samples
were obtained every 30 min. The subjects
remained supine in bed. Samples were
collected in tubes containing sodium ﬂu-
oride, EDTA, or heparin.
FSIVGTT
An intravenous catheter was placed in
each forearm. The catheters were kept
open with normal saline. Heating pads
were used to maximize the blood ﬂow.
After blood samples were obtained at
20, 10, and 0 min, glucose (0.3
units/kg as 25% dextrose) was injected
intravenouslyattime0.Intravenousinsu-
lin (0.03 units/kg) (Humulin regular; Eli
Lilly) was administered at time 20 min.
Additional samples were obtained at 0, 2,
3,4,5,6,8,10,12,14,16,19,22,23,24,
25, 27, 30, 35, 40, 50, 60, 70, 80, 90,
100, 120, 140, 160, and 180 min. The
sampleswereanalyzedforglucoseandin-
sulin. Acute insulin response (AIRg),
-cell function, insulin sensitivity index
(Si), and disposition index were calcu-
lated using the MINMOD Millennium
software (13).
Laboratory assays
Glucose was measured with a YSI 2300
STAT Plus Glucose & Lactate Analyzer
(YSILifeSciences,YellowSprings,OH)or
a Bayer Dax-48 system analyzer (Bayer
Diagnostics, West Haven, CT). Triglycer-
ide, cholesterol, and HDL cholesterol
were measured using a Poly-Chem Sys-
tem clinical chemistry analyzer (Poly-
medco, Cortlandt Manor, NY) or an
Olympus AU 600 autoanalyzer (Olym-
pus, Melville, NY). The coefﬁcients of
variation (CVs) were 1% for glucose,
3.5% for cholesterol, 4% for triglyceride,
and 3.6% for direct HDL. Insulin, leptin,
and adiponectin were measured using ra-
dioimmunoassay kits (Millipore, St.
Charles, MO) with CVs of 8.2, 4.3, and
6.5%, respectively. Insulin was also mea-
sured by chemiluminescence (Bayer Di-
agnostics). High-sensitivity C-reactive
protein (hs-CRP) was measured using a
highly sensitive latex–enhanced immu-
nonephelometric assay with both inter-
assay and intraassay CVs 5% or
immunoturbidimetry with an image ana-
lyzer (Hitachi 917; Quest Diagnostics)
with an intraassay CV of 8.7%.
Calculations
Peripheral insulin resistance was assessed
by calculating Matsuda’s sensitivity index
(ISIMatsuda), from the formula (10,000/
square root of [(fasting glucose  fasting
insulin)  (mean glucose  mean insulin
during OGTT)]), and Si was calculated by
applying the MINMOD program to
FSIVGTT data. Hepatic insulin resistance
was calculated by homeostasis model as-
sessment (HOMA), [(fasting insulin [mi-
crounits per milliliter]  fasting glucose
[milligrams per deciliter]/405)], and the
quantitative insulin sensitivity check in-
dex (QUICKI), 1/[log (fasting insulin) 
log(fastingglucose)]).Earlyinsulinsecre-
tion, the insulinogenic index, was calcu-
lated by dividing the increases in insulin
and glucose in the ﬁrst 30 min of the
OGTT (	Insulin 0–30/	Glucose 0–30) and by
calculating AIRg from FSIVGTT. Pancre-
atic function was assessed by calculating
theareaunderthecurve(AUC)forinsulin
and calculating -cell function during
FSIVGTT. -Cell compensation for insu-
lin resistance was assessed by calculating
the disposition index from AIRg and Si.
Statistical analysis
Statistical analyses were performed using
SAS statistical software (version 9.1; SAS
Institute, Cary, NC). Data were ﬁrst ex-
amined to identify any signiﬁcant varia-
tions between the populations from two
sites, UC Davis versus Yale School of
Medicine.Theagedistributionofthesub-
jects from Yale was shifted to younger
ages. In addition, age appeared to be con-
founded with BMI. Therefore, the pooled
data were analyzed by including age and
BMI as covariates in all of the subsequent
statistical analyses. After correction for
age and BMI, the association between
study site and any outcome was attenu-
ated toward the null.
Descriptive statistics were calculated.
ASpearmancorrelationcoefﬁcientandits
P value for signiﬁcance of correlation
were calculated to assess the magnitude
and direction of an association between
two given outcomes based on their
ordered ranks. The data were log-
transformed to improve the normality of
residuals and homoscedasticity of errors
where appropriate before statistical anal-
ysis. Group comparisons for mean in the
cross-sectional outcome were performed
by ANCOVA, adjusted for the baseline
values and covariates (age and BMI).
When the overall difference among the
groupmeanswassigniﬁcantinANCOVA,
post hoc pairwise group comparisons
were conducted using Bonferroni multi-
ple comparisons to identify the groups
with different means. The longitudinal
trajectories of 120-min changes in glu-
cose and insulin level were estimated by a
repeated-measures ANOVA. Individual
trajectories of change in glucose and in-
sulin level over ﬁve time points, observed
every 30 min over 2 h, were estimated
from linear random-effects models. Each
observed level was entered as the depen-
dent variable. Group (i.e., type of glucose
intolerance), time (in 30 min), and a
group  time interaction term were en-
tered as independent variables. The coef-
ﬁcients for the interaction term were used
to estimate the additional changes in glu-
coseandinsulinlevelovertimeassociated
with type of glucose intolerance. To ac-
count for between-subject heterogeneity
in the change of glucose or insulin level,
intercept and time were modeled as ran-
dom effects. Multiple comparisons were
controlled by the Bonferroni method
where appropriate. Two-sided P  0.05
was considered signiﬁcant.
RESULTS— Forty-six of 143 women
with PCOS (32%) had glucose tolerance
abnormalities.Sixteen(11%)hadIFG,10
(7%) had IGT, and 20 (14%) had CGI.
Theremaining97women(68%)hadnor-
mal glucose tolerance (NGT). Different
ethnic groups were similarly distributed
among NGT, IFG, IGT, and CGI. None of
the minorities were overrepresented in
any of the groups.
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IFG, IGT, and CGI groups
The IGT group was older and the IFG
group was more obese than the NGT
group (Table 1). By deﬁnition, the IFG,
IGT, and CGI groups had higher glucose
levels than the NGT group. All glucose-
intolerant groups had higher fasting insu-
lin than the NGT group (IFG 131  16
pmol/l, IGT 112  22 pmol/l, and CGI
145  12 pmol/l vs. NGT 88  5 pmol/l,
P  0.0002). The difference between the
fasting insulin values of the CGI and IGT
groups was also signiﬁcant (P  0.0047).
Insulin resistance
Both IFG and CGI groups had lower
ISIMatsuda values than the NGT groups
(2.12  0.29 and 1.90  0.28 vs. 4.61 
0.34, P  0.0004 and P  0.0001, re-
spectively)(Table1,Fig.2).In68women
who underwent FSIVGTT, differences in
Sididnotreachsigniﬁcance(NGT3.47
0.60, IFG 1.58  0.34, IGT 2.46  0.29,
and CGI 2.27  0.44, P  0.1468). On
the other hand, the disposition index was
signiﬁcantly reduced in the CGI group
compared with the NGT group (987 
296 vs. 1,615  236, P  0.0234). The
CGI group also had lower serum adi-
ponectinthantheNGTgroup(6.240.8
vs. 11.1  1.1 ng/ml, P  0.0096). Com-
pared with the NGT group, both IFG and
CGIgroupshadhigherHOMA(6.10.9
and 6.4  0.5 vs. 3.3  0.2, P  0.0006
and P  0.0001) and lower QUICKI
(0.30  0.006 and 0.30  0.004 vs.
0.33  0.003, P  0.0009 and P 
0.0001).
Insulin response
Compared with the NGT group, the IFG
group had an overall increase in insulin
responseduringanOGTT,andthediffer-
ences were signiﬁcant at every time point
(Table 1, Fig. 1), whereas the IGT and
CGIgroupsexhibitedadelayedresponse.
DuringtheﬁrsthalfoftheOGTT,theIFG
group had higher insulin levels than the
CGI group (30 min 820  42 vs. 508 
54 pmol/l and 60 min 1,032  54 vs.
738  72 pmol/l, P  0.001 for both).
After60min,theinsulinresponsepattern
changed; at 120 min the CGI group had
higherinsulinthantheIFGgroup(996
34vs.58345pmol/l,P0.001).In68
Table 1—Clinical and biochemical variables of the women with PCOS with NGT, IFG, IGF, and CGI
NTG IFG IGT CGI P (ANOVA)
n 97 16 10 20
Anthropometric
Age (years) 26.1  0.8 30.9  2.2 35.8  2.4† 30.6  1.7 0.0003
Weight (kg) 89.0  2.6 108.1  4.4* 84.7  7.5 101.4  5.2 0.0001
BMI (kg/m
2) 32.9  0.8 38.7  1.5* 33.1  2.9 38.1  1.8 0.0072
Fasting glucose (mmol/l) 4.9  0.0 6.1  0.2 5.1  0.1 6.0  0.1 0.0001
Insulin (pmol/l) 88  5 131  16 112  22 145  12 0.0002
Adiponectin (ng/ml)† 11.1  1.1 8.4  1.1 8.2  1.0 6.2  0.8* 0.0132
HOMA 3.3  0.2 6.1  0.9* 4.4  0.3 6.4  0.5* 0.0001
QUICKI 0.33  0.003 0.30  0.006* 0.32  0.011 0.30  0.004* 0.0001
OGTT
	Glucose0–30 2.4  0.1 3.4  1.0 4.0  0.5 2.9  0.5 0.0012
	Insulin0–30 446  34 689  124 395  82 462  70 0.3,141
Insulinogenic index 257  46 268  68 104  23 154  11 0.5,114
AUCGlucose 0–30 3.1  0.0 3.9  0.1* 3.6  0.1* 3.7  0.1* 0.0001
AUCInsulin 0–30 156  11 238  38* 155  30 188  22 0.049
AUCGlucose 0–120 12.8  0.2 16.1  0.6* 18.1  0.6* 18.3  0.8*‡ 0.0001
AUCInsulin 0–120 973  69 1,470  197* 1,170  197 1,461  172* 0.0001
ISIMatsuda 4.61  0.34 2.12  0.29* 2.76  0.62* 1.90  0.28* 0.0001
FSIVGTT†
Si† 3.47  0.68 1.58  0.34 2.46  0.31 2.27  0.44 0.1468
AIRg† 655  106 725  204 583  152 471  83 0.482
-Cell function† 236  25 266  55 350  76 317  31 0.0901
Disposition index† 1,615  236 879,187 1,225  226 988  296* 0.0238
CVD risk factors
Triglyceride (mmol/l) 1.22  0.07 1.29  0.16 1.78  0.29 1.29  0.14 0.2421
Cholesterol (mmol/l) 4.89  0.10 4.65  0.20 4.99  0.21 4.91  0.22 0.7987
LDL cholesterol (mmol/l) 3.03  0.10 2.99  0.22 3.10  0.11 3.22  0.19 0.8518
HDL cholesterol (mmol/l) 1.23  0.30 1.08  0.04 1.09  0.11 1.10  0.10 0.1678
hs-CRP (mg/l) 5.8  0.8 6.4  1.5 4.3  1.5 6.4  1.3 0.4786
Androgens
Testosterone (nmol/l) 2.46  0.10 2.43  0.21 2.53  0.35 3.09  0.24 0.0722
SHBG (nmol/l) 42.1  3.7 27.5  2.5 37.4  2.5 35.5  4.8 0.3932
FAI 9.1  0.7 8.8  4.4 5.4  2.0 11.1  1.3 0.1633
DHEAS (
mol/l) 0.59  0.03 0.57  0.09 0.46  0.10 0.54  0.08 0.6062
Data are means  SEM. *P  0.05 compared with the NGT group. †Studies done in the subpopulation of n  68 (NGT 36, IFG 8, IGT 8, and CGI 16). ‡P  0.05
compared with the IFG group. CVD, cardiovascular disease; DHEAS, dehydroepiandrosterone sulfate; FAI, free androgen index.
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there were no signiﬁcant differences in
AIRg(P0.4842)or-cellfunction(P
0.0901).
Insulin response in NGT tertiles,
divided based on insulin resistance
The IFG and CGI groups had similar in-
sulin resistance based on HOMA (6.1 
0.9 vs. 6.4  0.5), QUCKI (0.30  0.006
vs. 0.30  0.004), and ISIMatsuda (2.12 
0.29vs.1.900.28)butdifferentinsulin
response patterns (Table 2) (Fig. 1). Insu-
lin response in insulin-resistant subjects
with NTG was also investigated. When
divided into tertiles based on ISIMatsuda,
the insulin-resistant (NGT-IR) tertile was
similar to subjects with IFG and CGI,
based on their HOMA (5.6  0.3),
QUICKI (0.30  0.002), and ISIMatsuda
(1.90  0.09). Their BMI (39.9  1.2
kg/m
2)wassimilartothoseofthesubjects
with IFG (38.7  1.5 kg/m
2) and CGI
(38.1  1.8 kg/m
2). The NGT-IR group
had higher a insulinogenic index than the
IFG group (421  130 vs. 268  68, P 
0.05).
Differences among the NGT tertiles
The tertiles were referred to as insulin-
sensitive (NGT-IS), intermediate (NGT-
IN), and NGT-IR (Table 2) (Fig. 2). In
these tertiles, fasting glucose and insulin
increased stepwise (from 4.8  0.02 to
5.00.02andto5.10.02mmol/l,P
0.0001 and from 41  2t o7 9 2 and to
146  2 pmol/l, respectively, P 
0.0001). The NGT-IN and NGT-IR ter-
tiles had higher BMI, fasting glucose,
HOMA, 	Insulin0–30, hs-CRP, and free
androgen index and lower QUICKI and
HDL cholesterol than the NGT-IS tertile.
Inaddition,theNGT-IRtertilehadhigher
insulinogenic index, AUCGlucose 0–120,
AUCInsulin 0–120, and triglyceride and
lower sex hormone–binding globulin
thantheNGT-IStertile.Evenaftercorrec-
tion for BMI, differences in fasting glu-
cose, fasting insulin, 	Insulin0–30,
AUCGlucose 0–120, AUCInsulin 0–120, and
HDL cholesterol remained signiﬁcant.
Next, partial correlations among in-
sulin resistance parameters, cardiovascu-
lar risk factors, and androgens were
calculated after adjustment for the differ-
ences in BMI. Plasma triglyceride and hs-
CRP correlated directly with HOMA (r 
0.316 and 0.253, P  0.009 and P 
0.037, respectively) and inversely with
ISIMatsuda (r  0.282 and 0.306, P 
0.020 and 0.011, respectively).
Figure 1—Changes in glucose and insulin during OGTTs. A and B:  , NGT, n  97; Œ with
broken line, IFG, n  16; F, IGT, n  10; f, CGI, n  20. C: , NGT-IS, n  33; f, NGT-IN,
n32; ,NGT-IR,n32;Œwithbrokenline,IFG,n16.¤,P0.05comparedwithNGT-IR.
†P  0.05 compared with IFG. Data are means  SEM. a, P  0.05 compared with NGT; b, P 
0.05 compared with IFG; c, P  0.05 compared with IGT.
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onstrated that, ﬁrst, patients with PCOS
with IFG exhibited severe peripheral in-
sulin resistance and developed IFG de-
spite having an increased early insulin
response. Second, having normal glucose
levels during an OGTT did not indicate
normal insulin sensitivity or a low risk for
cardiovascular disease. Third, in the NGT
group, the BMI, sex hormone–binding
globulin, HDL cholesterol, and hs-CRP
levels appeared to have value in assessing
insulin resistance. Because we did not
have a control group of age- and weight-
matched women with normal reproduc-
tive function, we cannot conclusively
state that these ﬁndings are speciﬁc to pa-
tients with PCOS. However, our observa-
tions differ signiﬁcantly from those
obtained from middle-aged men and
women (14).
Diabetes risk increases with increas-
ing age and obesity (15). We found age
and weight to be important in develop-
ment of glucose intolerance and insulin
resistance, respectively (Tables 1 and 2).
Per deﬁnition, glucose levels were
higherinpatientswithIFG,IGT,andCGI
compared with patients with NGT. Insu-
lin responses of patients with IFG, IGT,
or CGI were not decreased. In fact,
AUCInsulin-120 was higher in both patients
with IFG and CGI, indicating that pa-
tients with PCOS can develop IFG and
CGI in the presence of hyperinsulinemia.
This was consistent with the ﬁndings of
Kulshreshtha et al. (12), who reported in-
creased insulin responses in patients with
PCOS with IGT/CGI or type 2 diabetes.
The time course of the insulin response
was the most signiﬁcant difference be-
tweenpatientswithIFGversusthosewith
IGT and CGI. Patients with IFG had a
brisk early insulin response that declined
during the second half of OGTT. In con-
trast,patientswithCGIandIGTexhibited
a decreased early insulin response fol-
lowed by delayed hyperinsulinemia. Pre-
vious reports showed similar response
patterns in those with IFG versus those
with IGT and CGI among subjects with-
out PCOS (12,14,16,17).
The brisk, early insulin response of
patients with IFG appeared to be speciﬁc
to PCOS because several studies in differ-
ent populations, ethnic groups, sex, and
agedistributionshavereporteddecreased
cumulative and early insulin response in
patients with IFG (14,17–20), although a
recent report in healthy nondiabetic men
and women showed an increased insulin
response(16).Theonlyavailablestudyin
PCOS demonstrated an increased insulin
response similar to ours (12).
InpatientswithPCOSwhohaveIGT,
the early and cumulative insulin re-
sponses(AUCInsulin-30andAUCInsulin-120)
did not differ signiﬁcantly from the re-
sponses of those with NGT, whereas
Kulshreshtha et al. (12) reported in-
creased insulin response in glucose-
intolerant patients with PCOS. However,
their study did not distinguish between
IGT and CGI, and the subjects were less
obese and of different ethnicities.
Studiesusingintravenousglucosetol-
erance tests in subjects without PCOS re-
ported that AIRg was decreased by 30%




n 33 32 32
Anthropometric
Age (years) 26.4  1.23 25.9  1.5 25.9  1.5 0.9641 0.449
BMI (kg/m
2) 27.4  1.0 31.6  1.2† 39.9  1.2†‡ 0.0001 —
Fasting
Glucose 4.8  0.02 5.0  0.002† 5.1  0.02†‡ 0.0001 0.0001
Insulin 41  27 9  2† 146  2†‡ 0.0001 0.0001
HOMA 1.44  0.10 2.9  0.1† 5.6  0.3†‡ 0.0001 0.0001
QUICKI 0.37  0.004 0.33  0.002† 0.30  0.002†‡ 0.0001 0.0001
OGTT
	Glucose0–30 2.2  0.3 2.3  0.2 2.6  0.2‡ 0.3,801 0.4358
	Insulin0–30 235  23 391  32† 736  73†‡ 0.0001 0.001
Insulinogenic index 134  26 221  45I 421  130†§ 0.0355 0.3425
AUCGlucose 0–120 11.6  0.4 13.0  0.3† 14.2  0.3†§ 0.0001 0.0006
AUCInsulin 0–120 463  32 781  29† 1,689  129†‡ 0.0001 0.0001
ISIMatsuda 8.12  0.6 3.71  0.12† 1.90  0.09†‡ 0.0001 0.0001
CVD risk factors
Triglyceride (mmol/l) 0.91  0.07 1.18  0.09 1.51  0.17† 0.0006 0.1873
Cholesterol (mmol/l) 4.76  0.14 5.04  0.17 4.86  0.18 0.4407 0.1721
LDL cholesterol (mmol/l) 2.73  0.19 3.25  0.17 3.14  0.14 0.0671 0.1361
HDL cholesterol (mmol/l) 1.43  0.07 1.25  0.05† 1.03  0.05†‡ 0.0001 0.0359
hs-CRP (mg/l) 1.9  0.3 5.9  2.1† 10.6  1.9†‡ 0.0001 0.1055
Androgens
Testosterone 2.25  0.14 2.53  0.14 2.60  0.21 0.2176 0.3996
SHBG (nmol/l) 57.9  7.7 37.9  7.0 25.0  3.3† 0.0025 0.0661
FAI 6.6  1.0 10.1  1.4† 12.8  1.7†‡ 0.0010 0.0741
DHEAS (
mol/l) 0.61  0.0.6 0.61  0.06 0.54  0.07 0.4783 0.8567
DataaremeansSEM.*P1,signiﬁcancebyANCOVA;P2,signiﬁcancebyANCOVAafteradjustmentforBMI.†P0.05comparedwiththeNGTgroup.‡P0.05
compared with the IFG group. §P  0.05 compared with the IFG group shown in Table 1, analyzed using the Bonferroni multiple-comparisons procedure in
ANCOVA. DHEAS, dehydroepiandrosterone sulfate; FAI, free androgen index.
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with IGT (20–22). As seen in Table 1,
AIRgdidnotdecreaseinourpatientswith
PCOS with IFG. Taken altogether, these
ﬁndings indicate that patients with PCOS
can develop fasting hyperglycemia and
glucose intolerance even with increased
early and cumulative insulin responses.
The literature indicates that primary
sites of insulin resistance differ in IFG,
IGT, and CGI (9,10,14): hepatic in IFG;
peripheral in IGT; and both hepatic and
peripheralinCGI.Thesedistinctionscan-
not be made without using a hyperinsu-
linemicclamp.Thesurrogatemeasuresof
hepatic insulin resistance include HOMA
and QUICKI. Consistent with the litera-
ture, we found increased HOMA and de-
creased QUICKI only when fasting
glucose was impaired (IFG/CGI) but not
in IGT (Table 1). In contrast with the lit-
erature, the surrogates for peripheral in-
sulin resistance, ISIMatsuda and Si,o fo u r
IFGgroupweresimilartothoseoftheIGT
and CGI groups, indicating that patients
with PCOS with isolated IFG also have
peripheral insulin resistance.
The cause of IFG was an enigma be-
cause this group had signiﬁcant early and
late hyperinsulinemia. Thus, we com-
pared the IFG group to subjects with
equal insulin resistance with NTG (NGT-
IR). Although the NGT-IR group and
those with IFG had similar HOMA,
QUICKI, and ISIMatsuda values, the
NGT-IRgrouphadahigherinsulinogenic
index. As shown in Fig. 1, patients with
IFG also had decreased overall insulin se-
cretion relative to the degree of insulin
resistance.
The studies of tertiles demonstrated
that patients with PCOS who have NGT
can still be severely insulin-resistant. In
addition, cardiovascular risk factors and
hyperandogenemia worsen before overt
hyperglycemia. Consistent with these
ﬁndings, a recent report indicated that
low HDL cholesterol levels correlate with
hyperinsulinemia in PCOS (23). Previous
studies had found increased cardiovascu-
lar risk factors only in subjects with IGT
and CGI without PCOS (11,21).
Weproposethenaturalcourseofglu-
cose intolerance in PCOS as follows. In-
sulin resistance increases with weight
gain, as suggested by the stepwise in-
crease in BMI in the NGT tertiles (Fig. 2).
As long as insulin response can compen-
sate, plasma glucose remains within the
“normal” range. A relatively small de-
crease in overall insulin response results
in isolated IFG. A decrease in the early
insulin response results in IGT/CGI, even
with late hyperinsulinemia. Factors lead-
ing to impairment of the early versus
overall response are not known, although
genetic factors may be important (4,24).
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